Post on 08-Jan-2018
description
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM THOMSON REUTERS Your use of these materials is subject to the terms and conditions hereof. Please read the disclaimer carefully before using these materials. 2005/2006 Expenditure on biotech derived entities had remained constant % of total R&D expenditure Major companies are defined as those spending US$ 1.8 billion in 2006 on ethical pharmaceutical R&D. Mid and Other companies are defined as those spending